Calreticulin exposure on malignant blasts predicts a cellular anticancer immune response in patients with acute myeloid leukemia
about
Concepts and mechanisms underlying chemotherapy induced immunogenic cell death: impact on clinical studies and considerations for combined therapiesPrognostic and Predictive Value of DAMPs and DAMP-Associated Processes in CancerTargeting the innate immune system as immunotherapy for acute myeloid leukemiaAutophagy, autophagy-associated adaptive immune responses and its role in hematologic malignanciesImmunogenic versus tolerogenic phagocytosis during anticancer therapy: mechanisms and clinical translationMechanisms of Translocation of ER Chaperones to the Cell Surface and Immunomodulatory Roles in Cancer and Autoimmunity.Cell death in disease: from 2010 onwardsInhibition of HIF-1α by PX-478 enhances the anti-tumor effect of gemcitabine by inducing immunogenic cell death in pancreatic ductal adenocarcinoma.Combinatorial strategies for the induction of immunogenic cell death.High-level secretion of native recombinant human calreticulin in yeast.Resistance to anticancer vaccination effect is controlled by a cancer cell-autonomous phenotype that disrupts immunogenic phagocytic removalDNA-mediated adjuvant immunotherapy extends survival in two different mouse models of myeloid malignanciesMany faces of DAMPs in cancer therapy.Clinical Manifestation of Calreticulin Gene Mutations in Essential Thrombocythemia without Janus Kinase 2 and MPL Mutations: A Chinese Cohort Clinical Study.The critical roles of endoplasmic reticulum chaperones and unfolded protein response in tumorigenesis and anticancer therapiesThe Mutation Profile of Calreticulin in Patients with Myeloproliferative Neoplasms and Acute Leukemia.Calreticulin exposure by malignant blasts correlates with robust anticancer immunity and improved clinical outcome in AML patients.Immune parameters affecting the efficacy of chemotherapeutic regimens.Targeting malignant mitochondria with therapeutic peptides.Calreticulin gene mutations in myeloproliferative neoplasms without Janus kinase 2 mutations.The role of the immunosuppressive microenvironment in acute myeloid leukemia development and treatment.Dissecting physical structure of calreticulin, an intrinsically disordered Ca2+-buffering chaperone from endoplasmic reticulum.A stressful microenvironment: opposing effects of the endoplasmic reticulum stress response in the suppression and enhancement of adaptive tumor immunity.Novel Therapies for Acute Myeloid Leukemia: Are We Finally Breaking the Deadlock?Calreticulin, a therapeutic target?DAMP-Induced Allograft and Tumor Rejection: The Circle Is Closing.Overexpression of calreticulin contributes to the development and progression of pancreatic cancer.Immunogenic cell death: can it be exploited in PhotoDynamic Therapy for cancer?Immunological metagene signatures derived from immunogenic cancer cell death associate with improved survival of patients with lung, breast or ovarian malignancies: A large-scale meta-analysisThe immune contexture in cancer prognosis and treatment.Calreticulin is a secreted BMP antagonist, expressed in Hensen's node during neural induction.The ratio of CD8+/FOXP3 T lymphocytes infiltrating breast tissues predicts the relapse of ductal carcinoma in situ.Calreticulin promotes immunity and type I interferon-dependent survival in mice with acute myeloid leukemia.Calreticulin is an effective immunologic adjuvant to tumor-associated antigens.Analysis of apoptosis methods recently used in Cancer Research and Cell Death & Disease publications.Combination of CALR and PDIA3 is a potential prognostic biomarker for non-small cell lung cancer.ATP Release from Chemotherapy-Treated Dying Leukemia Cells Elicits an Immune Suppressive Effect by Increasing Regulatory T Cells and Tolerogenic Dendritic Cells.Calreticulin: Challenges Posed by the Intrinsically Disordered Nature of Calreticulin to the Study of Its Function.Immunogenic and Non-immunogenic Cell Death in the Tumor Microenvironment.Calreticulin and type I interferon: An unsuspected connection.
P2860
Q26781215-25B08EF0-BDEC-4CAD-91CF-465948EA8926Q26795466-CB6AA672-50A1-46D0-AD36-E2CD181A1B8DQ27015876-A117C88E-4309-4D32-B70E-8917C4E7A531Q28072922-7F3A656B-0F1F-47FB-9C9E-059F5248DD8BQ28386858-6346F8DA-C129-4E3B-89A6-A03C34222E86Q35025948-EBE3AC0A-8B6D-4282-B17B-47A0230148BEQ35269870-92A8FE6B-2BF8-4C75-83AB-48CD821982CBQ35273555-7BF98F69-516E-48F9-85AC-E38D785B4C8CQ35535140-AE5CB1CA-887E-4CB2-B1F8-48C77B77D4B5Q36169179-B34CF7CE-3DF2-465C-B3F6-4E5C864F56A4Q36413628-9F538160-1DD9-438F-8244-B42CB7E81A7EQ36544893-CDAADD35-67FA-4506-BE33-E3409A299DF8Q36907117-BBF378A5-2634-4170-B18E-C289EC8EFD41Q37157892-F894250D-4C96-4878-83B7-5AA388A44038Q37285838-84715C81-B66A-495B-9DB2-5EC22EAC86E1Q37417434-1D403BC6-759A-4062-84DB-3B9D0DFDD929Q37545824-AAEF092E-43E8-4B37-9FD3-92D52732A588Q37848665-E4C4574D-443F-4402-8906-1CDF4130D619Q38040407-8DE7C3C5-7D9A-457D-922D-4C79FFF3A666Q38239217-7144945C-5F9E-4E91-842D-B5B62645D08FQ38250205-A74B56CB-3686-4152-A338-969EC3EF5A1DQ38288151-1653899D-5110-4BBC-9D69-3A36537BEC90Q38379620-7ECF1CF4-13A4-4EC6-8ABC-A94AF274A351Q38664735-9F3D2C46-960B-4CAD-B4B1-23C41786FAB7Q38766974-794DDB2E-BBBA-4094-AA56-BB22F2B44234Q38928826-04F0E00A-AAF7-4AEC-AE20-C023A752B7B7Q39058690-95ACC2A3-78A2-4838-88E6-0FBA73E74CFEQ39178654-02A1042E-FB70-4302-A132-456588BD7A02Q39281286-9AA78E93-BC6E-48ED-A22A-BB4A7ECFDEE8Q39456999-502A6C76-651D-4F08-B65E-C2FD484AFB58Q41565342-6673365C-6237-4BDC-BD40-E4ECA9C1E4BEQ41625138-34A8E222-3E1D-419F-95B4-778F7E3427C0Q42289788-2C9978D7-E344-4016-8F40-76C790C61996Q42376411-C5E5BE8A-4EAB-4977-BF5C-A190C31333EEQ42632659-5B9F97AD-59FD-46F0-A8A5-8F1591E56AD3Q47096994-33755FA3-F16D-411A-BD1F-95CB02682FCEQ47194065-0F102FAC-1FAF-474E-B8A7-85BB50C2D039Q47317019-E1C17315-E71D-425F-AA56-DB82546B8FDBQ49592900-4DF71E89-A033-4861-9B74-85B3834DDA3FQ53359618-65F8A449-0A8C-4750-A11C-047BA10AA385
P2860
Calreticulin exposure on malignant blasts predicts a cellular anticancer immune response in patients with acute myeloid leukemia
description
2010 nî lūn-bûn
@nan
2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Calreticulin exposure on malig ...... ts with acute myeloid leukemia
@ast
Calreticulin exposure on malig ...... ts with acute myeloid leukemia
@en
Calreticulin exposure on malig ...... ts with acute myeloid leukemia
@nl
type
label
Calreticulin exposure on malig ...... ts with acute myeloid leukemia
@ast
Calreticulin exposure on malig ...... ts with acute myeloid leukemia
@en
Calreticulin exposure on malig ...... ts with acute myeloid leukemia
@nl
prefLabel
Calreticulin exposure on malig ...... ts with acute myeloid leukemia
@ast
Calreticulin exposure on malig ...... ts with acute myeloid leukemia
@en
Calreticulin exposure on malig ...... ts with acute myeloid leukemia
@nl
P2860
P50
P356
P1476
Calreticulin exposure on malig ...... ts with acute myeloid leukemia
@en
P2093
A Tesnière
S De Botton
P2860
P356
10.1038/CDDIS.2010.82
P50
P577
2010-12-02T00:00:00Z